AllSci News
Tanabe’s oral MC1R agonist dersimelagon extends pain-free light exposure in Phase III EPP/XLP trial
Tanabe Pharma Corporation reported that dersimelagon, an investigational oral melanocortin 1 receptor (MC1R) agonist, significantly extended pain-free sunlight exposure in patients with…
Merck’s oral PCSK9 inhibitor enlicitide cuts LDL-C up to 65% in Phase III vs oral non-statins
Merck (NYSE: MRK) reported that enlicitide decanoate, its investigational oral PCSK9 inhibitor, cut LDL-C more than established oral non-statin therapies in adults…
Viridian Therapeutics' elegrobart meets primary endpoint in Phase III active thyroid eye disease trial
Viridian Therapeutics (Nasdaq: VRDN) reported Phase III data from the REVEAL-1 trial showing that elegrobart, a subcutaneous anti-IGF-1R monoclonal...
United Therapeutics' Tyvaso meets primary endpoint in Phase III for IPF
United Therapeutics (Nasdaq: UTHR) reported that treprostinil inhalation solution (Tyvaso) met the primary endpoint in the TETON-1 Phase III trial for...
BridgeBio files NDA for BBP-418 in limb-girdle muscular dystrophy type 2I/R9
BridgeBio Pharma submitted a New Drug Application to the US FDA on 30 March 2026 for oral BBP-418, seeking approval for the treatment of individuals living...
Amgen’s Imdylltra, Zymeworks’ Ziihera among 5 CHMP recommendations
The European Medicines Agency released its monthly update on approval recommendations from the Committee for Medicinal Products for Human Use (CHMP), with…
Aurinia expands autoimmune portfolio via Kezar acquisition
Aurinia Pharmaceuticals Expands Autoimmune Portfolio via $6.955/Share Acquisition of Kezar Life Sciences
Pfizer partner RemeGen takes 4th China indication for HER2-ADC disitamab vedotin, in HER2-low breast cancer
IMPORTANT NOTICE: The source material describes a regulatory approval by China's NMPA — not a submission or filing. The article brief requests coverage of a...
Biogen's litifilimab meets Phase II endpoint in cutaneous lupus erythematosus trial
Biogen (Cambridge, Mass.) reported that litifilimab met the primary endpoint in the Phase II portion of the AMETHYST Phase II/III trial in cutaneous lupus...
Delonix takes engineered outer membrane vesicle meningitis vaccine into first-in-human trial in Australia
Delonix Bioworks, a clinical-stage biotechnology company based in Shanghai and Perth, has initiated first-in-human dosing of the DX-104 vaccine, a MenB OMV...
FDA approves Biogen's high dose Spinraza regimen for spinal muscular atrophy
The US FDA has approved a high dose regimen of Spinraza (nusinersen) for the treatment of spinal muscular atrophy, the agency and developer Biogen announced...
Vor Bio raises USD 75m in private placement led by TCGX
Vor Bio (Nasdaq: VOR), a Boston-based clinical-stage biotechnology company focused on autoimmune diseases, announced a USD 75 million private placement led...
PRISM BioLab and Receptor.AI collaborate on AI-guided drug discovery targeting protein-protein interactions
PRISM BioLab and Receptor.AI Enter Drug Discovery Collaboration to Target Protein-Protein Interactions with AI-Guided Platform
PMV Pharmaceuticals Publishes First-in-Human Rezatapopt p53 Reactivator Data in Advanced Solid Tumors
PMV Pharmaceuticals, a Princeton-based precision oncology company listed on Nasdaq as PMVP, has published Phase 1 results from its PYNNACLE study of...
Incannex advances IHL-42X development strategy following positive Phase 2 obstructive sleep apnea results
Incannex Healthcare, a Melbourne and New York-based clinical-stage biopharmaceutical company, announced an updated clinical development strategy for IHL-42X...
The AllSci Brief
Systematic R&D and deal news. Daily.